title: Metadherin regulates epithelial-mesenchymal transition in carcinoma.
abstract: Metadherin (MTDH) was first identified in primary human fetal astrocytes exposed to HIV-1 in 2002 and then recognized as an important oncogene mediating tumorigenesis, progression, invasiveness, and metastasis of carcinomas. Epithelial-mesenchymal transition (EMT) is a vital process in embryonic development, organ repair, and cancer progression. MTDH and EMT have also been proved to be related to the prognosis of patients with cancers. Recent studies reveal a relationship between MTDH overexpression and EMT in some malignancies. This review highlights the overexpression of MTDH and EMT in cancers and their correlations in clinical studies. Positive correlations have been established between MTDH and mesenchymal biomarkers, and negative correlations between MTDH and epithelial biomarkers have also been established. Furthermore, experiments reveal EMT regulated by MTDH, and some signal pathways have been established. Some anticancer drugs targeting MTDH and EMT are introduced in this review. Some perspectives concerning EMT regulation by MTDH are also presented in this review.
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China; Department of Urology, Xiangya Hospital, Central South University, Kai Fu District, People's Republic of China.
authors.forename: Zhao
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Kai Fu District, People's Republic of China.
authors.forename: Zheng-Yan
authors.initials: ZY
authors.lastname: Tang
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Yin
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China; Department of Urology, Fujian Provincial Hospital, The Teaching Hospital of Fujian Medical University, Fuzhou, People's Republic of China.
authors.forename: Yong-Bao
authors.initials: YB
authors.lastname: Wei
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Kai Fu District, People's Republic of China.
authors.forename: Long-Fei
authors.initials: LF
authors.lastname: Liu
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Bin
authors.initials: B
authors.lastname: Yan
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Ke-Qin
authors.initials: KQ
authors.lastname: Zhou
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Ye-Qi
authors.initials: YQ
authors.lastname: Nian
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Yun-Liang
authors.initials: YL
authors.lastname: Gao
authors.affiliation: Department of Urology, The Second Xiangya Hospital, Central South University, Fu Rong District, Changsha, People's Republic of China.
authors.forename: Jin-Rui
authors.initials: JR
authors.lastname: Yang
keywords: biomarker; chemoprevention; oncogene; progression; signal pathway; therapeutic target